Breaking News, Collaborations & Alliances

Emergent Joins U.S. Govt.’s COVID-19 Vax Acceleration Efforts in Landmark Deal

Public-private partnership for COVID-19 vaccine development and manufacturing valued at approximately $628 million

By: Contract Pharma

Contract Pharma Staff

Emergent BioSolutions has been issued a task order under an existing contract with the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response (ASPR) at the U.S. Department of Health & Human Services (HHS), to deploy its contract development and manufacturing (CDMO) capacities, capabilities, and expertise to support the U.S. government’s efforts to accelerate delivery of COVID-19 vaccines.   This task order...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters